Tumor-derived exosomes reversing TMZ resistance by synergistic drug delivery for glioma-targeting treatment

Temozolomide (TMZ), as the first-line chemotherapeutic agent, relies on inducing DNA methylation of O6guanine for treating glioma. However, the survival time of patients are hardly exceeded 14.5 months, attributing to inevitable drug resistance and systematic toxicity after long-term administration. Herein, reassemblyexosomes (R-EXO) deriving from homologous glioma cells is proposed to carry TMZ and Dihydrotanshinone (DHT) for reversing drug resistance and enhancing lesions-targeted drug delivery, defined as R-EXO-TMZ/DHT (R-EXO-T/D). It is found that R-EXO-T/D share various advantages, including preferable blood-brain barrier (BBB)-penetrating ability with nanomemter size, tumor-homing accumulation with homologous effects, as well as potentiated antitumor activity with overcoming TMZ resistance and triggering immune response. This work develops a new strategy for site-specific drug delivery, showing a promising application of drug compatibility in glioma treatment.

Automated summary

This study proposes a new strategy for glioma treatment by using reassembly exosomes to carry drugs, which have good ability to cross the blood-brain barrier and tumor-targeting accumulation, overcoming drug resistance and triggering immune response.